Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $18.99 USD
Change Today +0.95 / 5.27%
Volume 321.9K
ADMS On Other Exchanges
As of 8:10 PM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gregory T. Went Ph.D.

Chairman and Chief Executive Officer, Adamas Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 29 board members in 2 different organizations across 1 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Gregory T. Went is a Co-founder and Chairman of NeuroMolecular and Tethys Bioscience Inc. Dr. Went Co-founded Adamas Pharmaceuticals, Inc. and has been its Chairman and Chief Executive Officer since 2000. He actively advises Tethys Bioscience Inc. in new technologies and financing. Dr. Went served as a Chief Operating Officer of DNA Sciences Inc. since January 2000. He spent a year at DNA Sciences and joined it in 2000 and managed the day-to-day internal operations ...

Read Full Background

Corporate Headquarters*

1900 Powell Street
Emeryville, California 94608

United States

Phone: 510-450-3500
Fax: 510-428-0519

Board Members Memberships*

Former Director
Co-Founder and Director
Former Chief Operating Officer and Director
Chairman and Chief Executive Officer


Carnegie Mellon University
University of California Berkeley

Other Affiliations*

Annual Compensation*

Total Annual Compensation$748,750

Stock Options*

All Other Compensation$1,724
Exercisable Options1,428,000
Total Number of Options1,428,000

Total Compensation*

Total Annual Cash Compensation$750,474
Total Short Term Compensation$748,750
Other Long Term Compensation$1,724
Total Calculated Compensation$9,402,232
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMS:US $18.99 USD +0.95


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADAMAS PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at